GlassScriptPhysician profile
Raphael A Argueta
NPI 1174744072
$725.69
in general payments reported to CMS, 2019-2025
12 companies · $65.56 in 2025
The $65.56 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.73 · 2020: $34.62 · 2021: $167 · 2022: $124 · 2023: $134 · 2024: $136 · 2025: $65.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $130.94 | 2019-2025 | Emgality, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $128.28 | 2021-2024 | Breztri, Airsupra |
| Pfizer INC. | $117.40 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $81.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $51.60 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $44.13 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $42.64 | 2023 | Quviviq |
| Novo Nordisk INC | $35.54 | 2021-2022 | |
| Amgen INC. | $29.94 | 2023 | Otezla |
| Exact Sciences Corporation | $29.84 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $21.34 | 2021 | |
| Mayne Pharma Commercial LLC | $12.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Argueta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.